(3.236.46.172)
[ij] [ij] [ij] 
Email id
 

Research Journal of Pharmaceutical Dosage Forms and Technology
Year : 2020, Volume : 12, Issue : 3
First page : ( 198) Last page : ( 204)
Print ISSN : 0975-234X. Online ISSN : 0975-4377.
Article DOI : 10.5958/0975-4377.2020.00034.8

A Review on IVIVC in The Development of Oral Drug Formulation: Data Obtained from Past Two Decades

Sirisha S.*

Sree Venkatsewara University of Pharmaceutical Sciences, Tirupathi, Chitoor (Dis)

*Corresponding Author E-mail: anjalisiri20@gmail.com

Online published on 10 August, 2020.

Abstract

Rapidity in Drug development can be achieved by researchers on finding a mathematical link between bioavailability and dissolution testing which leads to the concept of in vitro -in vivo correlation (IVIVC). This review article aimed to assess papers published in the last two decades regarding the use of the IVIVC in the development of oral formulations. A systematic search was done to retrieve articles reporting the use of the IVIVC in the oral formulation development in the period from 2000 to2020. The qualified studies were abstracted regarding the Biopharmaceutical Classification System (BCS)that explains the suitability of IVIVC, drug name, dosage form number of formulations, presence of the validation and predictability. The discussion was supported by these data, which allowed to address broadly strengths and weaknesses in thisarea. Moreover, a large database has been described in this article containing different IVIVC models, with different substances, providing support to scientists interested in this area.

Top

Keywords

In vitro -in vivo correlation, IVIVC, oral formulation, development, biopharmaceutics classification system, dissolution.

Top

  
║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
670,344,646 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.